High-dose riboflavin for migraine prophylaxis in children: a double-blind, randomized, placebo-controlled trial
MacLennan SC, Wade FM, Forrest KML, Ratanayake PD, Fagan E, Antony J
Published in Journal of Child Neurology
Methodology
Randomised, double-blind, placebo-controlled crossover trial of riboflavin 200 mg daily in 48 children with migraine.
Key Findings
No significant difference between riboflavin and placebo in attack frequency, severity or duration.
Conclusions
Riboflavin at this dose is not effective for migraine prophylaxis in children.
Limitations
Lower dose than adult trials; crossover design with possible carryover.
Supplements Studied
Riboflavin 200 mg daily produced no significant difference from placebo in children with migraine.
Outcomes Measured
Riboflavin did not reduce attack frequency in children compared with placebo.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.